Examples of molecular aberrations which are already used clinically as predictive markers for specific therapies include KRAS mutations, which predict lack of benefit from EGFR-targeting therapies, and BRAF mutations, for which the benefit of combinations of BRAF inhibitors and EGFR monoclonal antibodies has been shown in second-line metastatic disease treatment [67,68]. The gene discussed is BRAF; the disease is metastatic neoplasm.